PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Despite the significant achievements in the diagnosis and treatment of metastatic breast cancer (MBC), this condition remains substantially an incurable disease. In recent years, several clinical studies have aimed to identify novel molecular targets, therapeutic strategies, and predictive biomarker...

Descripción completa

Detalles Bibliográficos
Autores principales: Fusco, Nicola, Malapelle, Umberto, Fassan, Matteo, Marchiò, Caterina, Buglioni, Simonetta, Zupo, Simonetta, Criscitiello, Carmen, Vigneri, Paolo, Dei Tos, Angelo Paolo, Maiorano, Eugenio, Viale, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027489/
https://www.ncbi.nlm.nih.gov/pubmed/33842357
http://dx.doi.org/10.3389/fonc.2021.644737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027489/
https://www.ncbi.nlm.nih.gov/pubmed/33842357
http://dx.doi.org/10.3389/fonc.2021.644737

Ejemplares similares